Cambridge's AI-designed bird flu vaccine gave complete protection against diverse H5Nx variants in animal trials
The study in Cell Reports Medicine says stockpiled vaccines protected only about 50% of animals exposed to multiple variants; the next step is human clinical trials, which have not started.
Why it matters
Pandemic stockpiles hold vaccines matched to single strains that have already emerged, which leaves a gap when bird flu mutates. Cambridge and its spin-out DIOSynVax report a different approach: an AI-guided design meant to cover thousands of variants in one vaccine, and this is the team's third success with the method. The evidence so far is from animal trials only, and the authors say the next step is human clinical trials. Watch for a trial start, safety data and whether regulators accept animal-protection results as a basis for stockpiling decisions.
Key facts
- Published in Cell Reports Medicine
- Led by Prof. Jonathan Heeney, University of Cambridge, with spin-out DIOSynVax
- Complete protection against globally circulating, diverse H5Nx variants in animal trials
- Stockpiled vaccines protected only around 50% of animals
- Next step: human clinical trials